It was showed that dopamine and D2 agonists inhibit, dependent on VEGF, new blood vessels formation and reduce vascular permeability within neoplastic tumors such as gastric cancer [23], colorectal cancer [24], malignant melanoma [25], bone marrow tumors [26], ovarian cancer [27], small cell carcinoma lung cancer [28], non-small cell lung cancer [29], prostate cancer [30] and a tumor of the pituitary gland [31]. Here, VEGFA is linked to non-small cell lung carcinoma.